Rhythm Pharmaceuticals Statistics
Total Valuation
RYTM has a market cap or net worth of $6.50 billion. The enterprise value is $6.32 billion.
Important Dates
The last earnings date was Tuesday, August 5, 2025, before market open.
| Earnings Date | Aug 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RYTM has 66.42 million shares outstanding. The number of shares has increased by 4.74% in one year.
| Current Share Class | 66.42M |
| Shares Outstanding | 66.42M |
| Shares Change (YoY) | +4.74% |
| Shares Change (QoQ) | +0.99% |
| Owned by Insiders (%) | 0.68% |
| Owned by Institutions (%) | 81.90% |
| Float | 54.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 39.07 |
| Forward PS | 29.05 |
| PB Ratio | 48.66 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 40.46 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.79, with a Debt / Equity ratio of 0.85.
| Current Ratio | 2.79 |
| Quick Ratio | 2.45 |
| Debt / Equity | 0.85 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.90 |
Financial Efficiency
Return on equity (ROE) is -116.97% and return on invested capital (ROIC) is -41.11%.
| Return on Equity (ROE) | -116.97% |
| Return on Assets (ROA) | -29.39% |
| Return on Invested Capital (ROIC) | -41.11% |
| Return on Capital Employed (ROCE) | -72.94% |
| Revenue Per Employee | $552,251 |
| Profits Per Employee | -$665,859 |
| Employee Count | 283 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 1.09 |
Taxes
| Income Tax | -16,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +120.01% in the last 52 weeks. The beta is 2.39, so RYTM's price volatility has been higher than the market average.
| Beta (5Y) | 2.39 |
| 52-Week Price Change | +120.01% |
| 50-Day Moving Average | 77.32 |
| 200-Day Moving Average | 62.35 |
| Relative Strength Index (RSI) | 76.75 |
| Average Volume (20 Days) | 588,855 |
Short Selling Information
The latest short interest is 4.51 million, so 6.80% of the outstanding shares have been sold short.
| Short Interest | 4.51M |
| Short Previous Month | 4.79M |
| Short % of Shares Out | 6.80% |
| Short % of Float | 8.32% |
| Short Ratio (days to cover) | 4.86 |
Income Statement
In the last 12 months, RYTM had revenue of $156.29 million and -$188.44 million in losses. Loss per share was -$3.02.
| Revenue | 156.29M |
| Gross Profit | 139.48M |
| Operating Income | -177.44M |
| Pretax Income | -183.12M |
| Net Income | -188.44M |
| EBITDA | -175.91M |
| EBIT | -177.44M |
| Loss Per Share | -$3.02 |
Full Income StatementBalance Sheet
The company has $291.03 million in cash and $113.98 million in debt, giving a net cash position of $177.05 million or $2.67 per share.
| Cash & Cash Equivalents | 291.03M |
| Total Debt | 113.98M |
| Net Cash | 177.05M |
| Net Cash Per Share | $2.67 |
| Equity (Book Value) | 133.58M |
| Book Value Per Share | -0.19 |
| Working Capital | 231.23M |
Full Balance SheetCash Flow
| Operating Cash Flow | -107.72M |
| Capital Expenditures | n/a |
| Free Cash Flow | -107.72M |
| FCF Per Share | -$1.62 |
Full Cash Flow StatementMargins
Gross margin is 89.25%, with operating and profit margins of -113.53% and -117.16%.
| Gross Margin | 89.25% |
| Operating Margin | -113.53% |
| Pretax Margin | -117.17% |
| Profit Margin | -117.16% |
| EBITDA Margin | -112.56% |
| EBIT Margin | -113.53% |
| FCF Margin | n/a |
Dividends & Yields
RYTM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.74% |
| Shareholder Yield | -4.74% |
| Earnings Yield | -2.90% |
| FCF Yield | -1.66% |
Dividend DetailsAnalyst Forecast
The average price target for RYTM is $101.92, which is 4.15% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $101.92 |
| Price Target Difference | 4.15% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | 63.02% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RYTM has an Altman Z-Score of 3.44 and a Piotroski F-Score of 4.
| Altman Z-Score | 3.44 |
| Piotroski F-Score | 4 |